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ABSTRACT: Beyond the targeting of E3 ubiquitin ligases to
inhibit protein homeostasis, E3 ligase binders can be repurposed
as targeted protein degraders (PROTACs or molecular glues).
We sought to identify new binders of the VHL E3 ligase by
biophysical fragment-based screening followed by X-ray crystallo-
graphic soaking. We identiﬁed fragments binding at the
ElonginC:Cullin2 interface and a new cryptic pocket in VHL,
along with other potential ligandable sites predicted computa-
tionally and found to bind solvent molecules in crystal structures.
The elucidated interactions provide starting points for future
ligand development.
■ INTRODUCTION
E3 ubiquitin ligases covalently modify protein substrates by
catalyzing ubiquitin transfer from an E2-conjugating enzyme to
substrate proteins, thereby marking substrates for proteasomal
degradation.1 The largest subfamily of E3 ubiquitin ligases are
Cullin (Cul)-RING ligases (CRLs), which consist of large
modular assemblies comprising a RING domain, a scaﬀolding
Cul subunit, one or more adaptor proteins, and a substrate-
recognition subunit that binds to speciﬁc protein motifs
termed degrons.2,3 An archetypical example is the von Hippel−
Lindau protein (VHL), which functions as the substrate-
binding module of CRL2VHL, a CRL consisting of VHL, the
adaptor proteins Elongin B (EloB) and Elongin C (EloC),
Cul2, and Rbx1. VHL features a hydroxyproline (Hyp)
recognition site that targets for degradation post-translationally
hydroxylated hypoxia-inducible factor (HIF)-1α subunits.4,5
Crystal structures of VHL:EloC:EloB (VCB) in complex with
Hyp-containing HIF-1α peptides6,7 provided the structural
basis of Hyp recognition by VCB8 and inspired the design of
potent, cell-active Hyp-containing small-molecule inhibitors of
VHL.9−12
Beyond VHL, the substrate-recognition subunit of only few
other CRLs has been targeted using small molecules.3 Notably,
CRL binders can be converted into targeted protein degraders
by conjugating them to a ligand of a protein of interest.13
These bivalent compounds, also termed proteolysis-targeting
chimeras (PROTACs), have been developed to induce cellular
degradation of a wide range of protein targets, including
transcription factors, epigenetic targets, and kinases.14−17 We
have recently presented the ﬁrst crystal structure of VCB in
complex with a PROTAC and the target protein, highlighting
the importance of inducing stable and cooperative protein−
protein recognition around the target E3 ligase site.18
Exploiting such ternary complex recognition, we have also
shown that E3 ligase binders can be turned into avid dimerizers
that can induce an E3 ligase to destroy itself.19 Unlike
conventional protein inhibitors, the activity of PROTACs is
not dependent upon the biological function or perceived
druggability of the attachment sites.13,20 Therefore, ligandable
pockets in E3 ubiquitin ligases aside from the conventional
degron-recognition pocket could potentially be exploited to
anchor PROTACs or as molecular glues.3 So far, however,
ligandable pockets in VCB apart from the HIF-recognition site
remain unknown.
The successful small-molecule modulation of the function of
speciﬁc protein classes historically deemed intractable has
motivated a growing interest in developing technologies to
probe protein surfaces and identify secondary binding
sites.21,22 In particular, fragment screening by X-ray crystallog-
raphy and NMR has seen widespread application.23−26 From a
computational perspective, a variety of empirical-, grid-, and
force-ﬁeld based methods have been developed.27 Tools such
as SiteMap28 and FTMap29,30 are routinely used to predict and
analyze protein−ligand and protein−protein interfaces31,32 as
well as to study cryptic pockets.33 Mixed-solvent molecular
dynamics (MD) simulations enable solvent mapping with
protein ﬂexibility and explicit water, albeit at a substantial
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computational cost.34 This method has also been used to
detect and study allosteric sites, cryptic pockets, and hotspots
of intermolecular interaction.34−38
Herein we probe the surface of VCB to identify binding sites
by fragment-based screening and computational pocket
detection methods. The screening hits were validated by X-
ray crystallography, which revealed two novel ligandable
pockets: one involving the EloC:Cul interface and the other
involving a previously unknown cryptic pocket in VHL. In
addition, computational approaches located other potential
sites in VCB that bind solvent molecules in available
crystallographic data, suggesting that they could also be
ligandable.
■ RESULTS AND DISCUSSION
The biophysical cascade consisted of a primary screen of over
1200 rule of three-compliant fragments from the Maybridge
library using diﬀerential scanning ﬂuorimetry (DSF) and of
144 fragments randomly picked from the same library using
one-dimensional 1H NMR spectroscopy.40 Screening hits were
validated by NMR spectroscopy and subsequent X-ray
crystallography (Supporting Information (SI), Figure S1).
DSF monitors the unfolding temperature of a protein using a
ﬂuorescent dye that preferentially binds to unfolded proteins.
We screened our fragment library, assayed as singletons,
against both VCB and VCB preincubated with HIF-1α peptide
(VCBH). We reasoned that this approach could aid
identiﬁcation and direct discrimination between binders of
the HIF site and binders elsewhere in the complex. DSF hits
were deﬁned as fragments resulting in an increase in melting
temperature (ΔTm = Tm,protein+fragment − Tm,protein) of either
VCB or VCBH greater than 0.5 °C. In addition, ﬁve fragments
were considered hits due to their eﬀect on the overall melting
properties of VCB. In total, 65 unique hits were identiﬁed by
DSF (5.2% overall hit rate). In parallel, the ligand-based NMR
screen was performed in cocktails of three fragments. We
carried out a series of one-dimensional 1H NMR spectroscopy
binding experiments: water ligand observed gradient spectros-
copy (waterLOGSY), saturation transfer diﬀerence (STD),
and Carr−Purcell−Meiboom−Gill (CPMG) relaxation-edited
sequences.41 In these experiments, binding was assessed by
comparing the proton signals of the fragments in the presence
and in the absence of VCB. Speciﬁc binding to the VHL:HIF
interface was probed by subsequently monitoring displacement
of the ligand signals using the HIF-1α peptides 10-mer
DEALA-Hyp-YIPD or 19-mer DEALA-Hyp-YIPMDD-
DFQLRSF (Kd of 180 or 3 nM, respectively).
9,11 Fragments
were considered hits in the NMR screen if they showed
Figure 1. Fragment-based probing of the VHL:EloC:EloB E3 ubiquitin ligase. Chemical structure, F0 − Fc electron density omit map contoured at
3σ level, and X-ray crystal structure of fragment (A) MB235 in complex with VCB (PDB 6GMN), (B) MB1200 in complex with VCB (PDB
6GMX), and (C) MB756 in complex with VCBH (PDB 6GMR). Hydrogen bonds, ion−π interactions, and CO···CO contacts are
represented as yellow, cyan, and red dashed lines, respectively. (D) Superposition of the crystal structure of VCB in complex with MB235 and with
Cul2 (PDB 4WQO),39 colored deep teal and yellow. L3Cul2 and fragments MB235 and MB1200 occupy the same pocket in EloC. (E)
Superposition of the crystal structure of VCBH in complex with MB756 and of VCBH alone (PDB 4AJY),11 colored deep teal. Note that formation
of the cryptic pocket requires rearrangement of the gate amino acid R120VHL.
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binding in at least two of the three NMR experiments. This
resulted in 17 unique hits (11.8% overall hit rate).
In total, 82 fragments were selected as hits from these two
primary screens and subsequently validated by a second round
of NMR experiments (waterLOGSY, STD, and CPMG) as
cocktails of two for the DSF hits and as singletons for the
NMR hits. This secondary screen validated 18 of the 82 hits
identiﬁed in the primary screen (78.0% attrition rate). Notably,
all but one of the validated fragment hits were not displaced by
the HIF-1α peptide, suggesting that they may bind to other
sites on the VCB complex. To locate those potential new sites,
we soaked the 18 validated fragment hits in both VCB and
VCBH crystals, which have distinct crystal packing (P4122 for
VCB and P43212 for VCBH). This maximizes the likelihood of
success in the crystallographic fragment soaking by increasing
the combined solvent-exposed surface of the complex. The
soaking experiment yielded three fragments binding to sites in
VCB other than the HIF-recognition site in VHL (Figure 1
and SI, Figure S2 and Table S1), consistent with the NMR
data showing lack of competition by the HIF-1α peptide or a
Hyp-containing fragment binding weakly at the HIF site.11
Fragments MB235 and MB1200 (PDB 6GMN and 6GMX,
ΔTm = 0.7 and 1.2 °C against VCBH, respectively) bind to a
hydrophobic cleft in EloC that is only accessible in the VCB
crystals and occluded by crystal packing contacts in VCBH.
The newly identiﬁed binding site is deﬁned by EloC residues
E64, I65, P66, E102, M105, A106, and F109. Both compounds
share an aromatic portion that forms hydrophobic contacts and
a carbonyl group that occupies the same position in the two
crystal structures. The carbonyl carbon of the fragments
engages in a CO···CO contact with the backbone
carbonyl oxygen of E64EloC. Additionally, we observe ﬂexibility
of the E64EloC side chain in the cocrystal structures (Figure
1A,B). Superposition of EloC in complex with the fragments
and with Cul2 reveals that the fragments bind to the same
cavity used for recognition of L3Cul2 in the EloC:Cul2 interface
(Figure 1D), which we have recently probed using low-aﬃnity
peptides.42 In contrast, MB756 binds to both VCB and VCBH
crystals (PDB 6GMQ and 6GMR, respectively, ΔTm = 1.3 °C
against VCB) in a previously unknown cryptic pocket in VHL,
located over 15 Å away from the HIF-recognition site (Figure
2). The pyrrole ring of MB756 is inserted in a pocket in VHL
formed by VHL residues L118, F119, R120, G127, L128,
L129, E134, D197, and L201. The pocket is accessible only
after rearrangement of R120VHL, which acts as a gate amino
acid to accommodate the fragment (Figure 1E). Upon binding,
the pyrrole ring of the ligand engages in ion−π interactions
with R120VHL and E134VHL, and the phenolic hydroxyl group
protrudes away from the pocket to form hydrogen bonds to
the side chain of E160VHL and to a water molecule (Figure
1C). We used isothermal titration calorimetry (ITC) to
characterize the binding aﬃnity of the fragments to VCB (SI,
Figure S3). Dissociation constants of 5.0 and 6.7 mM were
obtained for MB756 and MB1200, respectively, resulting in a
ligand eﬃciency (LE) of 0.24 and 0.25 kcal/mol·heavy atom,
respectively. We have previously shown that fragments in this
range of aﬃnity and LE can be elaborated into high aﬃnity
binders.43 Together, the results support speciﬁc binding
interactions and qualify these pockets as ligandable, at least
to weak-aﬃnity fragments.
The newly discovered pockets in VCB are of substantial
interest in several research areas. First, we prove that the Cul
interface of EloC is ligandable and provide the ﬁrst ligand-
bound structures of EloC. Second, the cryptic pocket in VHL
Figure 2. Computational surface probing of the VHL:EloC:EloB E3 ligase. Ligandable pockets in VCB and sites predicted by SiteMap,28
FTMap,29,30 and mixed-solvent MD are highlighted. Pockets identiﬁed by SiteMap and FTMap are colored according to druggability classiﬁcation.
Consensus amino acids identiﬁed by mixed-solvent MD are colored according to the percentage of frames in the mixed-solvent MD simulation they
are in contact with a buried probe. Predicted hotspots 1−3 are highlighted and labeled.
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involves the most frequently occurring mutation in Chuvash
polycythemia, R200W, which prevents degradation of
phosphorylated tyrosine-protein kinase JAK2 through the
proteasome.44,45 Additionally, MB756 also contacts the
conserved P154VHL, which has been proposed to play an
important role in substrate poly ubiquitylation by CRLs.46
Thus, elaborated higher-aﬃnity binders could serve as
chemical biology tools to study E3 ligase activity and the
Chuvash disease at the molecular level. Notably, optimized
compounds binding to the new sites could also be converted
into targeted protein degraders, i.e., PROTACs.13 The
presence of several ligandable pockets in VCB additionally
sets an ideal, yet challenging, scenario to explore these and
other binding sites using computational pocket detection
methods. Thus, we next subjected VCB to a surface probing
campaign using SiteMap,28 FTMap,29,30 and mixed-solvent
MD.34
In the case of SiteMap and FTMap, we processed the whole
VCB complex using standard parameters. For the mixed-
solvent MD, we ﬁrst selected 15 fragment-size molecules with
varied physicochemical properties, chemotypes, and molecular
sizes as probes. We reasoned that exploration of protein
surfaces beyond druggability considerations requires thought-
ful yet bold probe selection. With this in mind, apart from
traditional probes typically used in solvent mapping, such as
benzene and isobutanol, we also considered biomimetics of
peptidic bonds, a zwitterionic species, a capped alanine, a
biaryl, a ﬂuorinated probe, and a sulfonamide (SI, Figure S4
and Table S2). Each probe was used to cosolvate VCB, and the
whole system was then subjected to MD simulations. Potential
binding sites were identiﬁed by recording consensus amino
acids surrounding probes buried in the protein surface during
the simulations.
Ligandable sites in VCB and those predicted computation-
ally are highlighted in Figure 2. The three pockets validated
experimentally provided a suitable opportunity to benchmark
the computational results. SiteMap and FTMap were very
successful in locating precisely the binding site of MB235 and
MB1200, and the MD approach suggested the importance of
surrounding amino acids M105EloC and D179VHL in non-
covalent recognition (SI, Figures S8 and S9). Consistent with
these predictions, an M105AEloC mutant resulted in a 35-fold
decrease in binding aﬃnity toward Cul2 compared to wild-type
EloC,48 and a K4ACul2 mutant peptide, which would prevent a
salt bridge between K4Cul2 and D179VHL, exhibited no binding
to VCB.42 The HIF-recognition site in VHL was properly
detected by the mixed-solvent MD method. However, FTMap
failed to locate it and SiteMap perceived it as undruggable,
consistent with the observation that only one fragment
targeting the HIF site emerged from our biophysical screen
(SI, Figure S1) and with the challenges in detecting binding of
fragments resulting from deconstructing ligands targeting this
interface.43 The methods also predicted a potentially druggable
large spot surrounding the cryptic pocket in VHL, suggesting
that there is promise in developing MB756 into a small-
molecule binder by engaging in farther favorable contacts (SI,
Figure S10). Because mixed-solvent MD can reveal cryptic
pockets,36,38 we next investigated whether the simulations
captured formation of the MB756 cavity in VHL. Indeed,
cosolvation of VCB with dioxopiperazine induced opening of
the pocket by triggering the required rearrangement of
R120VHL (Figure 3A,B). However, the probes did not occupy
the cavity during the simulations, presumably because of its
hydrophobic nature (Figure 1C).
Apart from detecting the three ligandable sites in VCB, we
were also interested in locating pockets elsewhere in the
Figure 3. Structural analysis of VHL:EloC:EloB E3 ubiquitin ligase sites. Surface representation of the cryptic pocket in VHL in (A) the
VCBH:MB756 cocrystal structure (PDB 6GMR) and in (B) a frame extracted from the MD trajectory of VCB cosolvated with dioxopiperazine.
Cul site in EloC upon superposition of VCB:Cul2 (PDB 4WQO),39 shown fogged, with (C) VCBH (PDB 4AJY)11 and with (D) Gustavus:EloCB
(PDB 2FNJ).47 Crystal structure of VCB with (E) glycerol in hotspot 1 (PDB 4AJY) and (F) acetate in hotspot 3 (PDB 4B9K).10 In (B), note the
rearrangement of gate amino acid R120VHL. In (C) and (D), amino acids of the symmetry-related protomer in the crystal are labeled with * and
colored bright orange. (E,F) Amino acids are colored according to the percentage of frames in the mixed-solvent MD simulation they are in contact
with a buried probe, as in Figure 2. Hydrogen bonds and salt bridges are shown as yellow dashed lines, and in (C) and (D) they are colored red if
they occur as part of a crystal contact.
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protein surface. SiteMap and FTMap proposed an additional,
albeit low-druggable, site in VHL (labeled as “hotspot 1” in
Figure 2). The same pocket was also identiﬁed by mixed-
solvent MD, as well as two unique sites in VHL and EloBC
(“hotspot 2” and “hotspot 3″, respectively). We mined the
Protein Data Bank (PDB) for crystal structures of VHL, EloC,
and EloB, aiming at identifying intermolecular contacts and
nonmodeled electron density in hotspots 1−3. Additionally,
we also inspected the binding sites of MB235, MB756, and
MB1200 for contacts that could inform future structure-based
fragment growing endeavors.
We gathered a total of 45 crystal structures: 36 crystal
structures of VCB and 9 crystal structures of complexes of
EloBC with viral factors or substrate-recognition subunits
other than VHL (SI, Table S5). While we could not identify
contacts involving the MB756 cryptic pocket, crystal contacts
were found in the HIF-recognition site (SI, Figure S11) and
the MB235/MB1200 pocket in EloC. In VCB:HIF-1α peptide
crystal structures, the EloC pocket is occupied by M568HIF‑1α
of a symmetry-related protomer (Figure 3C). In addition, the
side chain of E64EloC, which assists in Cul2-recognition by
VCB by hydrogen-bonding to S40Cul2, engages in a hydrogen
bond with the backbone of I566HIF‑1α. Similarly, in a crystal
structure of EloBC in complex with Gustavus (Gus), which is
the substrate-recognition subunit of the CRL5Gus E3 ubiquitin
ligase, the same cavity is occupied by L67Gus of a symmetry-
related unit, whereas E64EloC ﬂips and interacts with R65Gus
and H82Gus (Figure 3D). Notably, side chain ﬂexibility of
E64EloC is also observed in the presence of fragments MB235
and MB1200 (Figure 1A,B).
We extended the analysis to hotspots 1−3 predicted
computationally (Figure 2). We found a crystal structure of
VCB with glycerol bound to hotspot 1, sandwiched in a polar
cleft and engaging in two hydrogen bonds with R161VHL
(Figure 3E). In hotspot 2, we found crystal structures of
VCB with an elongated blob of nonmodeled electron density
that did not match a water molecule, suggesting that a small
solvent molecule may be trapped in the cavity (SI, Figure S12).
We also found several crystals of VCB in complex with HIF
small-molecule mimetics with a water molecule located in
hotspot 3. In some cases, the water is displaced by an acetate
that satisﬁes hydrophobic contacts with Y18EloC, I30EloC, and
I34EloB (Figure 3F).
■ CONCLUSIONS
In summary, we report crystal structures of the VHL:EloC:E-
loB E3 ubiquitin ligase in complex with fragment-based
screening hits. Two fragments bound to a small cavity at the
EloC:Cul interface, whereas another fragment bound to a
novel cryptic pocket in VHL. We also subject the VCB
complex to computational surface probing and study all
binding sites by systematic analysis of available crystal
structures of VHL, EloC, and EloB. We identify crystal
contacts in the EloC pocket that could inform future fragment
elaboration as well as solvents bound to potential hotspots
proposed computationally. Additionally, we detect formation
of the VHL cryptic pocket during the MD simulations by
rearrangement of the gate amino acid R120VHL, as observed
crystallographically.
The discovered cryptic pocket in VHL involves R200VHL,
which is highly mutated in Chuvash polycythemia, and
P154VHL, which has been proposed to play an important role
in substrate poly ubiquitylation by CRLs.45,46 The presented
fragment-bound structures of VCB will guide the development
and optimization of more potent ligands.43 Binders of the
cryptic pocket could be optimized into an allosteric ligand or
stabilizing probe for the Chuvash mutant protein, whereas
EloC binders could be used to disrupt the assembly of CRL2
ligases49 and to study the biology of EloC-containing E3
ligases. Additionally, elaborated binders of the newly identiﬁed
ligandable sites could also be converted into targeted protein
degraders. Indeed, the realization that persistent and
cooperative de novo protein−protein recognition, rather than
target binding aﬃnity, dictates preferential substrate degrada-
tion,18 and that suboptimal VHL ligands can render very
potent degraders,50 suggests that even weak binders of
secondary pockets in E3 ligases could be used as anchoring
ligands for PROTAC conjugation.
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■ ASSOCIATED CONTENT
*S Supporting Information
The Supporting Information is available free of charge on the
ACS Publications website at DOI: 10.1021/acs.jmed-
chem.8b00842.
Experimental section: protein expression and puriﬁca-
tion, DSF, ligand-observed NMR spectroscopy, crystal-
lization and structure determination, ITC, computa-
tional methods; ﬁgures and tables (PDF)
Molecular formula strings CSV)
Accession Codes
Atomic coordinates have been deposited in the Protein Data
Bank and will be released upon article publication. Accession
codes of VCB in complex with MB235 (PDB 6GMN), MB756
(PDB 6GMQ), MB1200 (PDB 6GMX), and VCBH in
complex with MB756 (PDB 6GMR).
■ AUTHOR INFORMATION
Corresponding Author
*Phone: +441382386230. Fax: +441382386373. E-mail: a.
ciulli@dundee.ac.uk.
ORCID
Xavier Lucas: 0000-0003-0887-3976
Alessio Ciulli: 0000-0002-8654-1670
Present Address
§I.V.M.: VIB-VUB Center for Structural Biology, Structural
Biology Brussels, Vrije Universiteit Brussel, Pleinlaan 2, 1050
Brussels, Belgium
Author Contributions
The manuscript was written through contributions of all
authors. All authors have given approval to the ﬁnal version of
the manuscript. X.L. and I.V.M. contributed equally.
Notes
The authors declare no competing ﬁnancial interest.
■ ACKNOWLEDGMENTS
Funding support is gratefully acknowledged from the European
Research Council (ERC-2012-StG-311460 DrugE3CRLs
Starting Grant to A.C.), the European Commission (H2020-
MSCA-IF-2015-806323 Marie Skłodowska-Curie Actions
Individual Fellowship to X.L. and EC PIEF-GA-2010-275683
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.8b00842
J. Med. Chem. 2018, 61, 7387−7393
7391
Marie-Curie Intra European Fellowship to I.V.M.), and the
Wellcome Trust (Strategic Awards 100476/Z/12/Z for
biophysics and drug discovery and 094090/Z/10/Z for
structural biology and X-ray crystallography to the Division
of Biological Chemistry and Drug Discovery at Dundee). We
thank Professor Chris Abell (Department of Chemistry,
Cambridge) for access to the fragment library, and the Soleil
and Diamond Light Source for beamtime and beamline
support at beamlines Proxima 1, i03, and i24.
■ ABBREVIATIONS USED
CRL, Cullin-RING E3 ubiquitin ligase; Cul, Cullin; DSF,
diﬀerential scanning ﬂuorimetry; CPMG, Carr−Purcell−
Meiboom−Gill; EloB, elongin B; EloC, elongin C; Gus,
Gustavus protein; HIF, hypoxia-inducible factor; Hyp,
hydroxyproline; ITC, isothermal titration calorimetry; LE,
ligand eﬃciency; MD, molecular dynamics; PROTAC,
proteolysis-targeting chimera; PDB, Protein Data Bank; STD,
saturation transfer diﬀerence; Tm, melting temperature; VHL,
von Hippel-Lindau protein; VCB, VHL:EloC:EloB; VCBH,
VCB:HIF-1α complex; waterLOGSY, water ligand observed
gradient spectroscopy
■ REFERENCES
(1) Hershko, A.; Ciechanover, A. The ubiquitin system. Annu. Rev.
Biochem. 1998, 67, 425−479.
(2) Lydeard, J. R.; Schulman, B. A.; Harper, J. W. Building and
remodelling Cullin-RING E3 ubiquitin ligases. EMBO Rep. 2013, 14,
1050−1061.
(3) Lucas, X.; Ciulli, A. Recognition of substrate degrons by E3
ubiquitin ligases and modulation by small-molecule mimicry
strategies. Curr. Opin. Struct. Biol. 2017, 44, 101−110.
(4) Ivan, M.; Kondo, K.; Yang, H.; Kim, W.; Valiando, J.; Ohh, M.;
Salic, A.; Asara, J. M.; Lane, W. S.; Kaelin, W. G., Jr. HIFα targeted for
VHL-mediated destruction by proline hydroxylation: implications for
O2 sensing. Science 2001, 292, 464−468.
(5) Jaakkola, P.; Mole, D. R.; Tian, Y. M.; Wilson, M. I.; Gielbert, J.;
Gaskell, S. J.; von Kriegsheim, A.; Hebestreit, H. F.; Mukherji, M.;
Schofield, C. J.; Maxwell, P. H.; Pugh, C. W.; Ratcliffe, P. J. Targeting
of HIF-α to the von Hippel-Lindau ubiquitylation complex by O2-
regulated prolyl hydroxylation. Science 2001, 292, 468−472.
(6) Min, J. H.; Yang, H.; Ivan, M.; Gertler, F.; Kaelin, W. G., Jr.;
Pavletich, N. P. Structure of an HIF-1α-pVHL complex: hydroxypro-
line recognition in signaling. Science 2002, 296, 1886−1889.
(7) Hon, W. C.; Wilson, M. I.; Harlos, K.; Claridge, T. D.; Schofield,
C. J.; Pugh, C. W.; Maxwell, P. H.; Ratcliffe, P. J.; Stuart, D. I.; Jones,
E. Y. Structural basis for the recognition of hydroxyproline in HIF-1α
by pVHL. Nature 2002, 417, 975−978.
(8) Loenarz, C.; Mecinovic, J.; Chowdhury, R.; McNeill, L. A.;
Flashman, E.; Schofield, C. J. Evidence for a stereoelectronic effect in
human oxygen sensing. Angew. Chem., Int. Ed. 2009, 48, 1784−1787.
(9) Buckley, D. L.; Van Molle, I.; Gareiss, P. C.; Tae, H. S.; Michel,
J.; Noblin, D. J.; Jorgensen, W. L.; Ciulli, A.; Crews, C. M. Targeting
the von Hippel-Lindau E3 ubiquitin ligase using small molecules to
disrupt the VHL/HIF-1α interaction. J. Am. Chem. Soc. 2012, 134,
4465−4468.
(10) Buckley, D. L.; Gustafson, J. L.; Van Molle, I.; Roth, A. G.; Tae,
H. S.; Gareiss, P. C.; Jorgensen, W. L.; Ciulli, A.; Crews, C. M. Small-
molecule inhibitors of the interaction between the E3 ligase VHL and
HIF-1α. Angew. Chem., Int. Ed. 2012, 51, 11463−11467.
(11) Van Molle, I.; Thomann, A.; Buckley, D. L.; So, E. C.; Lang, S.;
Crews, C. M.; Ciulli, A. Dissecting fragment-based lead discovery at
the von Hippel-Lindau protein:hypoxia inducible factor 1α protein-
protein interface. Chem. Biol. 2012, 19, 1300−1312.
(12) Galdeano, C.; Gadd, M. S.; Soares, P.; Scaffidi, S.; Van Molle,
I.; Birced, I.; Hewitt, S.; Dias, D. M.; Ciulli, A. Structure-guided
design and optimization of small molecules targeting the protein-
protein interaction between the von Hippel-Lindau (VHL) E3
ubiquitin ligase and the hypoxia inducible factor (HIF) α subunit with
in vitro nanomolar affinities. J. Med. Chem. 2014, 57, 8657−8663.
(13) Raina, K.; Crews, C. M. Targeted protein knockdown using
small molecule degraders. Curr. Opin. Chem. Biol. 2017, 39, 46−53.
(14) Zengerle, M.; Chan, K. H.; Ciulli, A. Selective small molecule
induced degradation of the BET bromodomain protein BRD4. ACS
Chem. Biol. 2015, 10, 1770−1777.
(15) Bondeson, D. P.; Mares, A.; Smith, I. E.; Ko, E.; Campos, S.;
Miah, A. H.; Mulholland, K. E.; Routly, N.; Buckley, D. L.; Gustafson,
J. L.; Zinn, N.; Grandi, P.; Shimamura, S.; Bergamini, G.; Faelth-
Savitski, M.; Bantscheff, M.; Cox, C.; Gordon, D. A.; Willard, R. R.;
Flanagan, J. J.; Casillas, L. N.; Votta, B. J.; den Besten, W.; Famm, K.;
Kruidenier, L.; Carter, P. S.; Harling, J. D.; Churcher, I.; Crews, C. M.
Catalytic in vivo protein knockdown by small-molecule PROTACs.
Nat. Chem. Biol. 2015, 11, 611−617.
(16) Winter, G. E.; Buckley, D. L.; Paulk, J.; Roberts, J. M.; Souza,
A.; Dhe-Paganon, S.; Bradner, J. E. Drug development. Phthalimide
conjugation as a strategy for in vivo target protein degradation. Science
2015, 348, 1376−1381.
(17) Robb, C. M.; Contreras, J. I.; Kour, S.; Taylor, M. A.; Abid, M.;
Sonawane, Y. A.; Zahid, M.; Murry, D. J.; Natarajan, A.; Rana, S.
Chemically induced degradation of CDK9 by a proteolysis targeting
chimera (PROTAC). Chem. Commun. (Cambridge, U. K.) 2017, 53,
7577−7580.
(18) Gadd, M. S.; Testa, A.; Lucas, X.; Chan, K. H.; Chen, W.;
Lamont, D. J.; Zengerle, M.; Ciulli, A. Structural basis of PROTAC
cooperative recognition for selective protein degradation. Nat. Chem.
Biol. 2017, 13, 514−521.
(19) Maniaci, C.; Hughes, S. J.; Testa, A.; Chen, W.; Lamont, D. J.;
Rocha, S.; Alessi, D. R.; Romeo, R.; Ciulli, A. Homo-PROTACs:
bivalent small-molecule dimerizers of the VHL E3 ubiquitin ligase to
induce self-degradation. Nat. Commun. 2017, 8, 830.
(20) Shimokawa, K.; Shibata, N.; Sameshima, T.; Miyamoto, N.;
Ujikawa, O.; Nara, H.; Ohoka, N.; Hattori, T.; Cho, N.; Naito, M.
Targeting the allosteric site of oncoprotein BCR-ABL as an alternative
strategy for effective target protein degradation. ACS Med. Chem. Lett.
2017, 8, 1042−1047.
(21) Guarnera, E.; Berezovsky, I. N. Allosteric sites: remote control
in regulation of protein activity. Curr. Opin. Struct. Biol. 2016, 37, 1−
8.
(22) Knapp, S. Emerging target families: intractable targets. Handb.
Exp. Pharmacol. 2015, 232, 43−58.
(23) Hajduk, P. J.; Huth, J. R.; Fesik, S. W. Druggability indices for
protein targets derived from NMR-based screening data. J. Med.
Chem. 2005, 48, 2518−2525.
(24) Edfeldt, F. N.; Folmer, R. H.; Breeze, A. L. Fragment screening
to predict druggability (ligandability) and lead discovery success. Drug
Discovery Today 2011, 16, 284−287.
(25) Ludlow, R. F.; Verdonk, M. L.; Saini, H. K.; Tickle, I. J.; Jhoti,
H. Detection of secondary binding sites in proteins using fragment
screening. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, 15910−15915.
(26) Amato, A.; Lucas, X.; Bortoluzzi, A.; Wright, D.; Ciulli, A.
Targeting ligandable pockets on plant homeodomain (PHD) zinc
finger domains by a fragment-based approach. ACS Chem. Biol. 2018,
13, 915−921.
(27) Wagner, J. R.; Lee, C. T.; Durrant, J. D.; Malmstrom, R. D.;
Feher, V. A.; Amaro, R. E. Emerging computational methods for the
rational discovery of allosteric drugs. Chem. Rev. 2016, 116, 6370−
6390.
(28) Halgren, T. A. Identifying and characterizing binding sites and
assessing druggability. J. Chem. Inf. Model. 2009, 49, 377−389.
(29) Brenke, R.; Kozakov, D.; Chuang, G. Y.; Beglov, D.; Hall, D.;
Landon, M. R.; Mattos, C.; Vajda, S. Fragment-based identification of
druggable ’hot spots’ of proteins using Fourier domain correlation
techniques. Bioinformatics 2009, 25, 621−627.
(30) Kozakov, D.; Hall, D. R.; Chuang, G. Y.; Cencic, R.; Brenke, R.;
Grove, L. E.; Beglov, D.; Pelletier, J.; Whitty, A.; Vajda, S. Structural
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.8b00842
J. Med. Chem. 2018, 61, 7387−7393
7392
conservation of druggable hot spots in protein-protein interfaces. Proc.
Natl. Acad. Sci. U. S. A. 2011, 108, 13528−13533.
(31) Vidler, L. R.; Brown, N.; Knapp, S.; Hoelder, S. Druggability
analysis and structural classification of bromodomain acetyl-lysine
binding sites. J. Med. Chem. 2012, 55, 7346−7359.
(32) Kozakov, D.; Hall, D. R.; Jehle, S.; Luo, L.; Ochiana, S. O.;
Jones, E. V.; Pollastri, M.; Allen, K. N.; Whitty, A.; Vajda, S. Ligand
deconstruction: Why some fragment binding positions are conserved
and others are not. Proc. Natl. Acad. Sci. U. S. A. 2015, 112, E2585−
2594.
(33) Beglov, D.; Hall, D. R.; Wakefield, A. E.; Luo, L.; Allen, K. N.;
Kozakov, D.; Whitty, A.; Vajda, S. Exploring the structural origins of
cryptic sites on proteins. Proc. Natl. Acad. Sci. U. S. A. 2018, 115,
E3416−E3425.
(34) Ghanakota, P.; Carlson, H. A. Driving structure-based drug
discovery through cosolvent molecular dynamics. J. Med. Chem. 2016,
59, 10383−10399.
(35) Ung, P. M.; Ghanakota, P.; Graham, S. E.; Lexa, K. W.; Carlson,
H. A. Identifying binding hot spots on protein surfaces by mixed-
solvent molecular dynamics: HIV-1 protease as a test case.
Biopolymers 2016, 105, 21−34.
(36) Kimura, S. R.; Hu, H. P.; Ruvinsky, A. M.; Sherman, W.; Favia,
A. D. Deciphering cryptic binding sites on proteins by mixed-solvent
molecular dynamics. J. Chem. Inf. Model. 2017, 57, 1388−1401.
(37) Arcon, J. P.; Defelipe, L. A.; Modenutti, C. P.; Lopez, E. D.;
Alvarez-Garcia, D.; Barril, X.; Turjanski, A. G.; Marti, M. A. Molecular
dynamics in mixed solvents reveals protein-ligand interactions,
improves docking, and allows accurate binding free energy
predictions. J. Chem. Inf. Model. 2017, 57, 846−863.
(38) Ghanakota, P.; van Vlijmen, H.; Sherman, W.; Beuming, T.
Large-scale validation of mixed-solvent simulations to assess hotspots
at protein-protein interaction interfaces. J. Chem. Inf. Model. 2018, 58,
784−793.
(39) Nguyen, H. C.; Yang, H.; Fribourgh, J. L.; Wolfe, L. S.; Xiong,
Y. Insights into Cullin-RING E3 ubiquitin ligase recruitment:
structure of the VHL-EloBC-Cul2 complex. Structure 2015, 23,
441−449.
(40) Silvestre, H. L.; Blundell, T. L.; Abell, C.; Ciulli, A. Integrated
biophysical approach to fragment screening and validation for
fragment-based lead discovery. Proc. Natl. Acad. Sci. U. S. A. 2013,
110, 12984−12989.
(41) Lepre, C. A.; Moore, J. M.; Peng, J. W. Theory and applications
of NMR-based screening in pharmaceutical research. Chem. Rev.
2004, 104, 3641−3676.
(42) Cardote, T. A. F.; Ciulli, A. Structure-guided design of peptides
as tools to probe the protein-protein interaction between Cullin-2 and
elongin BC substrate adaptor in Cullin RING E3 ubiquitin ligases.
ChemMedChem 2017, 12, 1491−1496.
(43) Dias, D. M.; Van Molle, I.; Baud, M. G.; Galdeano, C.;
Geraldes, C. F.; Ciulli, A. Is NMR fragment screening fine-tuned to
assess druggability of protein-protein interactions? ACS Med. Chem.
Lett. 2014, 5, 23−28.
(44) Pastore, Y. D.; Jelinek, J.; Ang, S.; Guan, Y.; Liu, E.; Jedlickova,
K.; Krishnamurti, L.; Prchal, J. T. Mutations in the VHL gene in
sporadic apparently congenital polycythemia. Blood 2003, 101, 1591−
1595.
(45) Russell, R. C.; Sufan, R. I.; Zhou, B.; Heir, P.; Bunda, S.;
Sybingco, S. S.; Greer, S. N.; Roche, O.; Heathcote, S. A.; Chow, V.
W.; Boba, L. M.; Richmond, T. D.; Hickey, M. M.; Barber, D. L.;
Cheresh, D. A.; Simon, M. C.; Irwin, M. S.; Kim, W. Y.; Ohh, M. Loss
of JAK2 regulation via a heterodimeric VHL-SOCS1 E3 ubiquitin
ligase underlies Chuvash polycythemia. Nat. Med. 2011, 17, 845−853.
(46) Liu, J.; Nussinov, R. The mechanism of ubiquitination in the
cullin-RING E3 ligase machinery: conformational control of substrate
orientation. PLoS Comput. Biol. 2009, 5, e1000527.
(47) Woo, J. S.; Imm, J. H.; Min, C. K.; Kim, K. J.; Cha, S. S.; Oh, B.
H. Structural and functional insights into the B30.2/SPRY domain.
EMBO J. 2006, 25, 1353−1363.
(48) Cardote, T. A. F.; Gadd, M. S.; Ciulli, A. Crystal structure of
the Cul2-Rbx1-EloBC-VHL ubiquitin ligase complex. Structure 2017,
25, 901−911 e903.
(49) Lin, H. C.; Yeh, C. W.; Chen, Y. F.; Lee, T. T.; Hsieh, P. Y.;
Rusnac, D. V.; Lin, S. Y.; Elledge, S. J.; Zheng, N.; Yen, H. S. C-
terminal end-directed protein elimination by CRL2 ubiquitin ligases.
Mol. Cell 2018, 70, 602−613 e603.
(50) Testa, A.; Lucas, X.; Castro, G.; Chan, K. H.; Wright, J.;
Runcie, A.; Gadd, M.; Harrison, W. T. A.; Ko, E. J.; Fletcher, D.;
Ciulli, A. 3-Fluoro-4-hydroxyprolines: synthesis, conformational
analysis and stereoselective recognition by the VHL E3 ubiquitin
ligase for targeted protein degradation. J. Am. Chem. Soc. 2018, 140,
9299.
Journal of Medicinal Chemistry Brief Article
DOI: 10.1021/acs.jmedchem.8b00842
J. Med. Chem. 2018, 61, 7387−7393
7393
